Tevogen Depreciation And Amortization from 2010 to 2025

TVGN Stock   1.21  0.07  6.14%   
Tevogen Bio Depreciation And Amortization yearly trend continues to be very stable with very little volatility. Depreciation And Amortization is likely to drop to about 160.5 K. Depreciation And Amortization is the systematic reduction in the recorded value of an intangible asset. This includes the allocation of the cost of tangible assets to periods in which the assets are used, representing the expense related to the wear and tear, deterioration, or obsolescence of physical assets and intangible assets over their useful lives. View All Fundamentals
 
Depreciation And Amortization  
First Reported
2010-12-31
Previous Quarter
227.2 K
Current Value
160.5 K
Quarterly Volatility
88.3 K
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Tevogen Bio financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Tevogen Bio's main balance sheet or income statement drivers, such as Depreciation And Amortization of 160.5 K, Interest Expense of 227.9 K or Selling General Administrative of 1.8 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or Days Sales Outstanding of 0.0. Tevogen financial statements analysis is a perfect complement when working with Tevogen Bio Valuation or Volatility modules.
  
Check out the analysis of Tevogen Bio Correlation against competitors.

Latest Tevogen Bio's Depreciation And Amortization Growth Pattern

Below is the plot of the Depreciation And Amortization of Tevogen Bio Holdings over the last few years. It is the systematic reduction in the recorded value of an intangible asset. This includes the allocation of the cost of tangible assets to periods in which the assets are used, representing the expense related to the wear and tear, deterioration, or obsolescence of physical assets and intangible assets over their useful lives. Tevogen Bio's Depreciation And Amortization historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Tevogen Bio's overall financial position and show how it may be relating to other accounts over time.
Depreciation And Amortization10 Years Trend
Slightly volatile
   Depreciation And Amortization   
       Timeline  

Tevogen Depreciation And Amortization Regression Statistics

Arithmetic Mean58,037
Geometric Mean20,200
Coefficient Of Variation152.07
Mean Deviation72,989
Median9,377
Standard Deviation88,258
Sample Variance7.8B
Range221.4K
R-Value0.73
Mean Square Error3.9B
R-Squared0.53
Significance0
Slope13,473
Total Sum of Squares116.8B

Tevogen Depreciation And Amortization History

2025160.5 K
2024227.2 K
2023197.5 K
2022230.8 K

About Tevogen Bio Financial Statements

Tevogen Bio investors utilize fundamental indicators, such as Depreciation And Amortization, to predict how Tevogen Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Depreciation And Amortization227.2 K160.5 K

Pair Trading with Tevogen Bio

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Tevogen Bio position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Tevogen Bio will appreciate offsetting losses from the drop in the long position's value.

Moving together with Tevogen Stock

  0.77PLX Protalix BiotherapeuticsPairCorr

Moving against Tevogen Stock

  0.46CRNX Crinetics PharmaceuticalsPairCorr
  0.44CDIO Cardio DiagnosticsPairCorr
The ability to find closely correlated positions to Tevogen Bio could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Tevogen Bio when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Tevogen Bio - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Tevogen Bio Holdings to buy it.
The correlation of Tevogen Bio is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Tevogen Bio moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Tevogen Bio Holdings moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Tevogen Bio can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Tevogen Bio Holdings is a strong investment it is important to analyze Tevogen Bio's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Tevogen Bio's future performance. For an informed investment choice regarding Tevogen Stock, refer to the following important reports:
Check out the analysis of Tevogen Bio Correlation against competitors.
You can also try the Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Tevogen Bio. If investors know Tevogen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Tevogen Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
0.35
Return On Assets
(5.42)
The market value of Tevogen Bio Holdings is measured differently than its book value, which is the value of Tevogen that is recorded on the company's balance sheet. Investors also form their own opinion of Tevogen Bio's value that differs from its market value or its book value, called intrinsic value, which is Tevogen Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Tevogen Bio's market value can be influenced by many factors that don't directly affect Tevogen Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Tevogen Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine if Tevogen Bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Tevogen Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.